It’s 100 percent fatal, hits its victims in the prime of their lives and has companies with prospective treatments either shutting down or spinning their wheels with trial holds and failures. Huntington’s disease might just top the list of intractable neurodegenerative diseases.
If you are not happy with the results below please do another search
50 search results for:
After examining the available information and hearing the testimony of CKD patients who participated in the clinical studies, the majority of the committee agreed the benefits of the medication outweighed its risks as a monotherapy.
New research out of McMaster University found a recently abandoned Bayer compound halted the growth of an aggressive form of pediatric medulloblastoma in mouse models.
The FDA has requested that Clovis Oncology limit the indication of its PARP inhibitor Rubraca as second-line maintenance therapy in recurrent ovarian cancer.
The head of the panel of 18 appointees, known as STIKO, said there was no clear case for broad use, citing a lack of data to rule out any rare side effects and no signs of the infection causing severe illness in otherwise healthy children.
Infections from some antibiotic-resistant pathogens known as superbugs have more than doubled in health care facilities in Europe, an EU agency said on Thursday, providing further evidence of the wider impact of the COVID-19 pandemic.
When Ebola broke out in Uganda in September, 10 doctors immediately stepped forward to work in an isolation unit at Fort Portal Regional Referral Hospital, but now only three are left.
Three Ebola vaccine candidates for a planned clinical trial are expected to be shipped to Uganda next week, World Health Organization Director-General Tedros Adhanom Ghebreyesus said on Wednesday.
AstraZeneca dosed the first patient in a Phase II portion of an ongoing trial assessing a PD-1/TIGIT bispecific antibody, triggering a $7.5 million milestone payment to partner, Compugen.
The acquisition fosters continued expansion of the network’s APAC presence.